FINWIRES · TerminalLIVE
FINWIRES

伊维尔德罗拉第一季度电力产量因产能提升而增长

By

-- 西班牙电力公司伊维尔德罗拉(Iberdrola)周三公布,第一季度电力产量同比增长1.6%,主要得益于装机容量增长3.8%。 截至3月31日的第一季度,净发电量为36.106太瓦时(TWh),其中25.62太瓦时来自可再生能源。 海上风电发电量猛增42%,达到2.639太瓦时;太阳能发电量增长1.7%,达到1.703太瓦时。另一方面,陆上风电发电量下降2.7%,至11.775太瓦时;水电发电量下降1.1%,至9.366太瓦时。 燃气联合循环发电厂的发电量激增42.5%,达到3.453太瓦时;而核电发电量则下降12.7%,至5.464太瓦时。 与此同时,伊维尔德罗拉的装机容量同比增长3.8%,达到58.877吉瓦,主要得益于新增的储能、太阳能和风能装机容量。 同期,电力和天然气供应量分别增长10.6%至27.132太瓦时和2.4%至15.196太瓦时。 在电网业务方面,公司输送的电力增长9.7%至68.645太瓦时,主要得益于供应点数量增长8.7%至3710万个。英国市场增长最为显著,电力输送量飙升72.6%至14.687太瓦时,供应点数量增长69.4%至610万个。 另一方面,由于供应点数量减少0.7%至100万个,美国市场的天然气输送量下降5.5%至25.582太瓦时。

Related Articles

Asia

ICBC Sells 50 Billion Yuan Bonds

Industrial and Commercial Bank of China (HKG:1398, SHA:601398) or ICBC completed the issue of 50 billion yuan of four-year bonds carrying an interest rate of 1.79%, according to a Wednesday Hong Kong bourse filing.The lender has a conditional redemption right at the end of the third year.The firm intends to use proceeds to improve its total loss-absorbing capacity.

$HKG:1398$SHA:601398
Asia

DFZQ's Profit Climbs 11% in Q1

Orient Securities (HKG:3958) or DFZQ recorded an 11% rise in attributable profit in the first quarter of 2026 to 1.59 billion yuan from 1.44 billion yuan after adjustment a year prior, according to a Wednesday Hong Kong bourse filing.The securities company's basic EPS rose to 0.19 yuan from 0.16 yuan in the corresponding period of the previous fiscal year.Operating income jumped 5.3% to 4.09 billion yuan from 3.88 billion yuan in the year-ago period.

$HKG:3958
Research

Research Alert: Ionis Reports Strong Q1 Led By Commercial Momentum; Raises Guidance

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Ionis delivered robust Q1 2026 results with total revenue surging to $246M (+87% Y/Y), fueled by strong commercial execution and approximately $95M in R&D milestone payments. Product sales reached $43M compared to just $6M in the prior year period, with TRYNGOLZA generating $27M (+350% Y/Y) and DAWNZERA contributing $16M (+125% sequential growth). The accelerating momentum across its independent launch portfolio demonstrates strong commercial execution, in our view. Management raised 2026 revenue guidance substantially to $875M-$900M (from $800M-$825M) and improved operating loss guidance to $425M-$475M (from $500M-$550M). The company also increased olezarsen peak sales guidance to over $3B from over $2B, reflecting growing confidence in the severe hypertriglyceridemia market opportunity. With multiple regulatory catalysts ahead, including potential approvals for olezarsen and zilganersen, we believe Ionis appears well-positioned for continued growth.

$IONS